The differential metabolite profiles of acute lymphoblastic leukaemic patients treated with 6-mercaptopurine using untargeted metabolomics approach
- 1 April 2014
- journal article
- Published by Elsevier in Clinical Biochemistry
- Vol. 47 (6) , 427-431
Abstract
No abstract availableKeywords
Funding Information
- Ministry of Higher Education Malaysia (FRGS 1175)
- Ministry of Science, Technology and Innovation, Malaysia (02-01-01-SF0280)
This publication has 20 references indexed in Scilit:
- Polymorphism of ITPA 94C>A and risk of adverse effects among patients with acute lymphoblastic leukaemia treated with 6-mercaptopurineJournal of Clinical Pharmacy and Therapeutics, 2011
- Cytosolic Phospholipase A2 and Lysophospholipids in Tumor AngiogenesisJNCI: Journal of the National Cancer Institute, 2010
- Oleamide suppresses lipopolysaccharide-induced expression of iNOS and COX-2 through inhibition of NF-κB activation in BV2 murine microglial cellsNeuroscience Letters, 2010
- Leukotriene E4–induced pulmonary inflammation is mediated by the P2Y12 receptorJournal of Experimental Medicine, 2009
- A sample extraction and chromatographic strategy for increasing LC/MS detection coverage of the erythrocyte metabolomeJournal of Chromatography B, 2008
- Acute lymphoblastic leukaemiaThe Lancet, 2008
- Metabolomics: A Global Biochemical Approach to Drug Response and DiseaseAnnual Review of Pharmacology and Toxicology, 2008
- Altered glucose metabolism in childhood pre-B acute lymphoblastic leukaemiaLeukemia, 2006
- Bile acids induce cyclooxygenase-2 expression in human pancreatic cancer cell linesCarcinogenesis, 2003
- Phosphomonoester concentrations differ between chronic lymphocytic leukemia cells and normal human lymphocytesLeukemia Research, 2002